News
Novavax scores narrower Covid vaccine approval
Digest more
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback